Back

PACIFIC-AMI - Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction .

28 August 2022 (08:52 - 09:04)
Organised by:
Congress Presentation Part of: HOT LINE SESSION 5 Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor John Alexander

Duke University Medical Center, Durham (United States of America)

11 More presentations in this session

Presentation thumbnail
INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation.
Professor G. Karthikeyan (New Delhi, IN)
Slides Video
Presentation thumbnail
Discussant review - INVICTUS.
Professor R. Lopes (Durham, US)
Slides Video
Presentation thumbnail
Panel discussion - INVICTUS.
Video
Presentation thumbnail
Discussant review - PACIFIC-AMI.
Doctor M. O'Donoghue (Boston, US)
Slides Video
Presentation thumbnail
Panel discussion - PACIFIC-AMI.
Video

Access the full session

Session thumbnail
HOT LINE SESSION 5
Video

The Event

Event poster

ESC Congress 2022

28 August 2022 08:52 CET
You may be interested in
thumbnail
Congress Presentation
Safety of the oral Factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF).
29 August 2022
thumbnail
Congress Presentation
Biomarker-guided risk management following acute coronary syndromes
30 August 2025
thumbnail
Congress Presentation
Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial
26 August 2022
thumbnail
Congress Presentation
LIBREXIA ACS: Milvexian after recent ACS
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources